TGFB1 and diabetic cardiomyopathy: Currently, Meng et al. [983] showed that silymarin ameliorates diabetic cardiomyopathy through the inhibition of TGF-β1/Smad signaling, suggesting that silymarin could have a potential role in diabetic cardiomyopathy treatment.